EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Core Insights - EyePoint Pharmaceuticals is set to present an update on its DURAVYU™ Phase 3 pivotal program for wet age-related macular degeneration (wet AMD) and additional analyses from the Phase 2 VERONA trial for diabetic macular edema (DME) at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 [1][6] Company Overview - EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, utilizing its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery [3][4] - The lead product candidate, DURAVYU™, is an investigational treatment for VEGF-mediated retinal diseases, combining vorolanib, a selective tyrosine kinase inhibitor, with Durasert E™ [3][5] - DURAVYU™ is currently in Phase 3 global pivotal trials for wet AMD, which is the leading cause of vision loss in individuals aged 50 and older in the U.S., and has recently completed a Phase 2 trial for DME [3][5] Pipeline Programs - EyePoint's pipeline includes EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E™ to potentially enhance outcomes in serious retinal diseases [4] - The Durasert drug delivery technology has been safely administered to thousands of patients across four FDA-approved products for various disease indications [4] Regulatory Status - Vorolanib is exclusively licensed to EyePoint for the localized treatment of all ophthalmic diseases outside of specific regions in Asia [5] - DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901, but it remains an investigational product and has not yet received FDA approval [5]